International

Biogen’s loss of Tecfidera US patent has major commercial implications

The company’s failure to provide an adequate written description mean that up to one third of its free cashflow is now under threat

Biogen’s loss of Tecfidera US patent has major commercial implications
Big Pharma facing shortage of late-stage assets as M&A dries up
23 Jun 2020

Big Pharma facing shortage of late-stage assets as M&A dries up

Pandemic has thrown a spanner in the works for large life sciences companies, which have fewer phase three novel drugs than at any point in the last decade

Takeda offloads yet more “non-core” assets with other deals likely to follow
18 Jun 2020

Takeda offloads yet more “non-core” assets with other deals likely to follow

The Japanese big pharma continues to divest drug rights to pay down its debt and fund desperately needed innovation

Latest

View all
15 Jun 2020

The University of California builds its patent portfolio, but not its royalty returns

The world-renowned school has seen its licensing income stall and that could force it to take a more aggressive line in securing ROI Read more

12 Jun 2020

Royalty Pharma’s $2 billion IPO target shows importance of patent monetisation in life sciences

The company’s public offering comes after years of growth and demonstrates the changing dynamics of an industry in which smaller R&D entities are becoming increasingly significant players Read more

2 Jun 2020

MPEG LA builds new biotech licensing programmes and remains hopeful on CRISPR pool

Trend suggests a growing similarity between patent monetisation models in the life sciences and high-tech sectors Read more

26 May 2020

WHO covid-19 IP pool launches this week without strong pharma support

Open and global sharing of patents, data and know-how is seen as a step too far by many life sciences innovators Read more

Designs

View all
20 May 2020

IP Hall of Fame 2020 inductees announced

A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more

28 Apr 2020

How IP owners have responded to the covid-19 challenge so far

Several innovators have already waived exclusivities, but big decisions for right holders lie ahead Read more

26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

Finance

View all
26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Mar 2020

Help us map the latest developments in the global IP market

There’s not long left to answer our annual IP benchmarking survey Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

13 Feb 2019

IPBC Global 2019 is shaping up to be the biggest and best of the series so far

Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco Read more

Frand/SEPS

View all
26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Mar 2020

Help us map the latest developments in the global IP market

There’s not long left to answer our annual IP benchmarking survey Read more

28 Feb 2020

The US has a mountain to climb in 5G network equipment

Patent analysis shows that American companies would need to make big plays if they want to catch the Chinese, but it is almost certainly too late already Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

Law & Policy

View all
21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

20 May 2020

IP Hall of Fame 2020 inductees announced

A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more

30 Apr 2020

IP is crucial to finding breakthrough covid-19 medicines, Novartis policy head states

“We are only in the position to tackle the pandemic, because of where the system has brought us so far,” says Corey Salsberg in an exclusive interview with IAM Read more

23 Apr 2020

AI has never been more important in the life sciences

Use of artificial intelligence and machine learning has produced an explosion in life sciences partnerships, while raising new IP questions Read more

Litigation

View all
20 May 2020

IP Hall of Fame 2020 inductees announced

A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more

18 May 2020

PGR decision provides much-needed clarity in fast-growing microbiome space

First post-grant decision in the technology sector nevertheless gives some hope to gut bacteria innovators, despite invalidating a key cancer treatment patent Read more

30 Apr 2020

IP is crucial to finding breakthrough covid-19 medicines, Novartis policy head states

“We are only in the position to tackle the pandemic, because of where the system has brought us so far,” says Corey Salsberg in an exclusive interview with IAM Read more

28 Apr 2020

How IP owners have responded to the covid-19 challenge so far

Several innovators have already waived exclusivities, but big decisions for right holders lie ahead Read more

Market Developments

View all
21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

18 May 2020

PGR decision provides much-needed clarity in fast-growing microbiome space

First post-grant decision in the technology sector nevertheless gives some hope to gut bacteria innovators, despite invalidating a key cancer treatment patent Read more

14 May 2020

Patent cliff fears drive through 2020’s second largest pharma deal

Despite an M&A slowdown amid coronavirus uncertainties, Alexion Pharmaceuticals has splashed out more than $1 billion in the face of imminent threats to its IP position in the US and Europe Read more

30 Apr 2020

IP is crucial to finding breakthrough covid-19 medicines, Novartis policy head states

“We are only in the position to tackle the pandemic, because of where the system has brought us so far,” says Corey Salsberg in an exclusive interview with IAM Read more

Non-Practising Entities

View all
21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

28 Apr 2020

How IP owners have responded to the covid-19 challenge so far

Several innovators have already waived exclusivities, but big decisions for right holders lie ahead Read more

16 Apr 2020

Exclusive: New IP policy to help forge partnerships on potential UK covid-19 vaccine

Licensing deals on crucial technologies expected in next two months, says Oxford University tech transfer chief, after scientist indicates significant progress in efforts to find coronavirus treatment Read more

9 Apr 2020

World leaders hatch further plans for accessibility of covid-19 IP rights

WHO to establish voluntary patent pool, while Greek Prime Minister calls for EU to buy rights to vaccines and tests Read more

Patent Pools

View all
21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

30 Apr 2020

IP is crucial to finding breakthrough covid-19 medicines, Novartis policy head states

“We are only in the position to tackle the pandemic, because of where the system has brought us so far,” says Corey Salsberg in an exclusive interview with IAM Read more

16 Apr 2020

Exclusive: New IP policy to help forge partnerships on potential UK covid-19 vaccine

Licensing deals on crucial technologies expected in next two months, says Oxford University tech transfer chief, after scientist indicates significant progress in efforts to find coronavirus treatment Read more

9 Apr 2020

World leaders hatch further plans for accessibility of covid-19 IP rights

WHO to establish voluntary patent pool, while Greek Prime Minister calls for EU to buy rights to vaccines and tests Read more

Patents Law

View all
21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

20 May 2020

IP Hall of Fame 2020 inductees announced

A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more

19 May 2020

Top 50 PCT representative firms revealed

Japan’s Shiga International Patent Office is number one on the list, with Fish & Richardson and Epping Hermann Fischer leading for the US and Europe respectively Read more

18 May 2020

PGR decision provides much-needed clarity in fast-growing microbiome space

First post-grant decision in the technology sector nevertheless gives some hope to gut bacteria innovators, despite invalidating a key cancer treatment patent Read more

Strategy

View all
21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

14 May 2020

Patent cliff fears drive through 2020’s second largest pharma deal

Despite an M&A slowdown amid coronavirus uncertainties, Alexion Pharmaceuticals has splashed out more than $1 billion in the face of imminent threats to its IP position in the US and Europe Read more

30 Apr 2020

IP is crucial to finding breakthrough covid-19 medicines, Novartis policy head states

“We are only in the position to tackle the pandemic, because of where the system has brought us so far,” says Corey Salsberg in an exclusive interview with IAM Read more

28 Apr 2020

How IP owners have responded to the covid-19 challenge so far

Several innovators have already waived exclusivities, but big decisions for right holders lie ahead Read more

Technology Licensing

View all
21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

14 May 2020

Patent cliff fears drive through 2020’s second largest pharma deal

Despite an M&A slowdown amid coronavirus uncertainties, Alexion Pharmaceuticals has splashed out more than $1 billion in the face of imminent threats to its IP position in the US and Europe Read more

30 Apr 2020

IP is crucial to finding breakthrough covid-19 medicines, Novartis policy head states

“We are only in the position to tackle the pandemic, because of where the system has brought us so far,” says Corey Salsberg in an exclusive interview with IAM Read more

28 Apr 2020

How IP owners have responded to the covid-19 challenge so far

Several innovators have already waived exclusivities, but big decisions for right holders lie ahead Read more

Trade Secrets

View all
21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

20 May 2020

IP Hall of Fame 2020 inductees announced

A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more

14 May 2020

Patent cliff fears drive through 2020’s second largest pharma deal

Despite an M&A slowdown amid coronavirus uncertainties, Alexion Pharmaceuticals has splashed out more than $1 billion in the face of imminent threats to its IP position in the US and Europe Read more

30 Apr 2020

IP is crucial to finding breakthrough covid-19 medicines, Novartis policy head states

“We are only in the position to tackle the pandemic, because of where the system has brought us so far,” says Corey Salsberg in an exclusive interview with IAM Read more

Valuation

View all
21 May 2020

Global calls for compulsory covid-19 patent licensing build

Scrutiny of biopharma innovators’ coronavirus IP strategies will continue to intensify in coming months as concerns mount about access to treatments Read more

14 May 2020

Patent cliff fears drive through 2020’s second largest pharma deal

Despite an M&A slowdown amid coronavirus uncertainties, Alexion Pharmaceuticals has splashed out more than $1 billion in the face of imminent threats to its IP position in the US and Europe Read more

16 Apr 2020

Exclusive: New IP policy to help forge partnerships on potential UK covid-19 vaccine

Licensing deals on crucial technologies expected in next two months, says Oxford University tech transfer chief, after scientist indicates significant progress in efforts to find coronavirus treatment Read more

14 Apr 2020

Biopharma deal-making loses momentum amid current uncertainties

Following a sharp drop in Q1, the purchase of patent-rich life sciences businesses may dry up this quarter as the covid-19 pandemic makes it more difficult to evaluate assets Read more

Find an expert